Loading
A phase 2/3 trial of JMT101, docetaxel and HB1801 in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT06319313 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 534 participants, started 2024-05-01 and due to reach its primary completion in 2026-07-01. Interventions recorded: JMT101; docetaxel; HB1801. Conditions listed: Squamous Cell Non-small Cell Lung Cancer. Primary outcome: Overall response rate (ORR); Overall Survival (OS); Incidence and severity of adverse events (AE) and serious adverse events (SAE). Lung eligibility wording from the registry: "Pathological diagnosis as sqNSCLC, with EGFR highly expressed, without other driver genes". No results are recorded here; the registry entry is the source.
Shares Squamous cell carcinoma of the lung, Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.